
Topic
FDA Approval
NDA, BLA, ANDA, 505(b)(2), label language, review packages, and approval-pathway interpretation.

Pricing & Access· July 18, 2026 · 18 min read
By Ran Chen#Oncology#FDA Approval#Specialty Pharmacy

Policy· July 16, 2026 · 24 min read
Companion diagnostic change control: FDA PMA supplement vs. EU IVDR
By Ran Chen#Companion Diagnostic#FDA Approval#EMA

Approvals· July 16, 2026 · 17 min read
Lipfendra (enlicitide) coverage: first oral PCSK9 inhibitor approval
By Ran Chen#Cardiovascular#PCSK9#FDA Approval

Approvals· July 16, 2026 · 19 min read
Revtorpyk (gedatolisib) coverage: breast cancer approval and billing
By Ran Chen#Oncology#Breast Cancer#FDA Approval

Pricing & Access· July 15, 2026 · 21 min read
COPD Access Landscape 2026: Inhaled Triple Therapy, Dupilumab, and Ensifentrine

Pricing & Access· July 15, 2026 · 18 min read
Heart Failure Access Landscape 2026: GDMT, Entresto Generic, Kerendia, and Verquvo
By Ran Chen#Heart Failure#Payer Criteria#Cardiovascular

Pricing & Access· July 15, 2026 · 19 min read
IPF Access Landscape 2026: Jascayd, Ofev Generic entry, and Pirfenidone Pricing

Pricing & Access· July 8, 2026 · 22 min read
Gilead Sciences Portfolio Dossier: The Biktarvy Cliff, Yeztugo PrEP, and an Oncology Reset
By Ran Chen#HIV PrEP#Generic Entry#Drug Pricing

Approvals· July 3, 2026 · 17 min read
Icotyde (icotrokinra) FDA approval and oral IL-23 psoriasis access
By Ran Chen#FDA Approval#Dermatology#Immunology

Approvals· July 3, 2026 · 17 min read
Lynavoy (linerixibat) FDA approval: first IBAT inhibitor for PBC pruritus
By Ran Chen#FDA Approval#GI and Liver#Rare Disease